{"id":7672,"date":"2025-08-07T13:31:14","date_gmt":"2025-08-07T13:31:14","guid":{"rendered":"https:\/\/stoxpo.com\/?p=7672"},"modified":"2025-08-07T13:31:14","modified_gmt":"2025-08-07T13:31:14","slug":"eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/","title":{"rendered":"Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Zepbound and Mounjaro Drive U.S. Sales, Yet Orforglipron Trial Results Raise Investor Concerns<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Eli Lilly (LLY) delivered a solid second-quarter earnings beat, but concerns over its experimental oral GLP-1 pill, orforglipron, overshadowed the strong financials and dragged the stock lower. Despite a 38% year-over-year jump in revenue, shares dipped in early trading Thursday and are down 4% year to date.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The pharmaceutical giant reported Q2 revenue of $15.56 billion, well above Wall Street\u2019s $14.69 billion estimate, with earnings per share of $6.31 versus expectations of $5.56. U.S. sales alone accounted for $10.81 billion, fueled by a 46% increase in sales volume of its GLP-1 blockbusters, Mounjaro and Zepbound. However, an 8% price decline slightly tempered overall growth.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Zepbound, in particular, continues to gain ground in the weight-loss market. According to JPMorgan, Zepbound prescriptions surged 225% year over year to 418,000 weekly prescriptions, surpassing Novo Nordisk&#8217;s Wegovy, which grew just 35% with 281,000 weekly prescriptions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Still, investor enthusiasm cooled over orforglipron, Eli Lilly\u2019s once-promising oral GLP-1 candidate. In late-stage trials, the highest dose saw a 25% patient dropout rate, raising red flags. Mizuho analyst Jared Holz pointed out that even the placebo group had a 29% dropout rate, calling the findings \u201codd\u201d and prompting calls for more clarity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company plans to file orforglipron\u2019s data with the FDA this year, with hopes to launch by 2026. In the meantime, Eli Lilly continues to benefit from Zepbound\u2019s dominance, capturing over 60% of new weight-loss prescriptions in the U.S.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CEO Dave Ricks summed it up: \u201cLilly delivered another quarter of strong performance,\u201d yet investors remain cautious about the long-term pipeline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/daxors-new-handheld-blood-volume-analyzer-gets-fda-green-light\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Daxor\u2019s New Handheld Blood Volume Analyzer Gets FDA Green Light<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zepbound and Mounjaro Drive U.S. Sales, Yet Orforglipron Trial Results Raise Investor Concerns Eli Lilly (LLY) delivered a solid second-quarter earnings beat, but concerns over its experimental oral GLP-1 pill, orforglipron, overshadowed the strong financials and dragged the stock lower. Despite a 38% year-over-year jump in revenue, shares dipped in early trading Thursday and are [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5518,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[361,309],"tags":[421,544,416,418,417],"coauthors":[454],"class_list":["post-7672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-large-cap","category-pharmaceuticals","tag-growth","tag-lly","tag-movers","tag-news","tag-stock-market"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Zepbound and Mounjaro Drive U.S. Sales, Yet Orforglipron Trial Results Raise Investor Concerns Eli Lilly (LLY) delivered a solid second-quarter earnings beat, but concerns over its experimental oral GLP-1 pill, orforglipron, overshadowed the strong financials and dragged the stock lower. Despite a 38% year-over-year jump in revenue, shares dipped in early trading Thursday and are [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-07T13:31:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock\",\"datePublished\":\"2025-08-07T13:31:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/\"},\"wordCount\":287,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"keywords\":[\"Growth\",\"LLY\",\"Movers\",\"News\",\"Stock Market\"],\"articleSection\":[\"Large-Cap\",\"Pharmaceuticals\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/\",\"name\":\"Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"datePublished\":\"2025-08-07T13:31:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/07\\\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock - Stoxpo","og_description":"Zepbound and Mounjaro Drive U.S. Sales, Yet Orforglipron Trial Results Raise Investor Concerns Eli Lilly (LLY) delivered a solid second-quarter earnings beat, but concerns over its experimental oral GLP-1 pill, orforglipron, overshadowed the strong financials and dragged the stock lower. Despite a 38% year-over-year jump in revenue, shares dipped in early trading Thursday and are [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/","og_site_name":"Stoxpo","article_published_time":"2025-08-07T13:31:14+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock","datePublished":"2025-08-07T13:31:14+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/"},"wordCount":287,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","keywords":["Growth","LLY","Movers","News","Stock Market"],"articleSection":["Large-Cap","Pharmaceuticals"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/","url":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/","name":"Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","datePublished":"2025-08-07T13:31:14+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/07\/eli-lilly-posts-strong-q2-earnings-but-glp-1-pill-disappointment-weighs-on-stock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=7672"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7672\/revisions"}],"predecessor-version":[{"id":7673,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7672\/revisions\/7673"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/5518"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=7672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=7672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=7672"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=7672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}